- DEPARTMENT SECTION: Biología Celular
- Name and code oin the Andalusian Research Plan (PAI): BIO-139
- Head of the PAI research group: Raul Luque Huertas
OncObesity and Metabolism
OncObesity and Metabolism
- IP: Raúl M. Luque Huertas
- Location:
- Edificio Severo Ochoa, 3ª planta. Campus de Rabanales. 14014. Córdoba.
- Edificio IMIBIC. Avda. Menéndez Pidal s/n. 14004 Córdoba.
- Contact: This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it. - (+34) 957 21 37 40
- Web: enlace
- RRSS: @OncMet27
- IP:
Raúl Miguel Luque Huertas
- INVESTIGADORES:
Antonio Jesús Martínez Fuentes
Juan Solivera Vela
André Morais Sarmento Borges Cabral
Álvaro Flores Martínez
Araceli García Martínez
Juan Manuel Jiménez Vacas
Antonio Carlos Fuentes Fayos
María Teresa González Serrano
María del Mar Moreno Rodríguez
- PREDOCTORALES:
Antonio Jesús Montero Hidalgo
Jesús Miguel Pérez Gómez
Prudencio Sáez Martínez
Francisco Porcel Pastrana
Miguel Eduardo García García
Ana de la Salud De la Rosa Herencia
Fernando Mata Ordóñez
Antonio Prats Escribano
Alejandro Cuenca Martagon
María Loreta Libero
María Teresa Sánchez Medianero
Rafael Sánchez Sánchez
Álvaro Toledano Delgado
Roberto Valverde Moyano
Juana María Vidal Miñano
Ignacio Gil Duque
José Hernández Hernández
Andrea Martínez Vara
- PERSONAL TÉCNICO-ADMINISTRATIVO:
María Ortega Bellido
Miguel Ángel Núñez Santos
Manolo Galán Cañete
Fernando López López
The OncoObesity and Metabolism Group is a basic-clinical multidisciplinary group composed of Postdocs researchers, PhD students, clinicians and laboratory technicians experts in different areas of the Biomedicine field. It is a stable and highly qualified research team that maintains continuous financial support through competitive calls (both public and private) and has a highly productive and qualitative scientific record (publication in prestigious international journals and patents).
We focus on the study of cellular, molecular and pathophysiological bases that underlie the development and progression of metabolic diseases (such as obesity and diabetes), tumor pathologies and cancer and, especially on the pathophysiological association and interaction between both pathologies, using human samples and cellular and preclinical models from a multiomic (genomics, transcriptomics and epi- transcriptomics, proteomics, metabolomics) and functional point of view. More specifically, we have a special interest in the study of the function of: 1) some endocrine-metabolic factors (hormonal systems); 2) the machineries that control the expression and secretion of inflammatory components (inflammasome); 3) regulators of the senescence-associated secretory phenotype (SASP), 4) factors associated with the regulation of the expression and secretion of miRNAs (DROSHA, DICER, etc.) and extracellular vesicles; 5) machineries and factors that control the RNA metabolism [splicing process (spliceosome), mRNA degradation (Non-sense Mediated mRNA decay (NMD)/ RNA-Exosome, and associated factors/variants], as well as 6) machineries responsible for maintenance of genomic stability (telomerase/shelterin).
The different research lines of our group have as a common aim: the identification of new diagnostic, prognostic and therapeutic opportunities in the interaction between metabolic dysregulations (mainly obesity) and tumoral pathologies, in order to promote their transfer to the Society and improve the Public Health Systems.
1. Título: Multiomic and integrative approach: deciphering the role of the periprostatic adipose tissue in the pathophysiological interaction between obesity and the prostate gland (OMICIN-ADIPRO) (PID2022-1381850B-I00). Institución Financiadora: Proyectos de generación del conocimiento del Ministerio de Ciencia e Innovación Periodo, desde: 2023 a: 2026 Cantidad: 398.750 € IP: Raúl Miguel Luque Huertas
2. Título: Identification of novel diagnostic, prognostic, and/or therapeutic targets in oligodendrogliomas associated with the dysregulation of gene expression and genomic instability mechanisms (PRYGN235048LUQU). Institución Financiadora: Proyectos Generales de la Asociación Española Contra el Cáncer Periodo, desde: 2023 a: 2026 Cantidad: 239.800 € IP: Raúl Miguel Luque Huertas
3. Título: Aproximación spliceosomica para desarrollar una herramienta personalizada de diagnóstico y pronóstico, con potencial impacto terapéutico en tumores cerebrales malignos (DTS23/00055) Institución Financiadora: Proyectos de Desarrollo Tecnológico en Salud. Instituto de Salud Carlos III (ISCIII) Periodo, desde: 2023 a: 2024 Cantidad: 101.200 € IP: Raúl Miguel Luque Huertas
4. Título: Aproximación spliceosómica para la identificación de biomarcadores diagnósticos, pronósticos y dianas terapéuticas en tumores cerebrales pediátricos (FINOCENTE02). Institución Financiadora: Fundación Inocente, Inocente Periodo, desde: 2022 a: 2024 Cantidad: 105.000 € IP: Raúl Miguel Luque Huertas
5. Título: Contribución de los mecanismos de regulación del metabolismo del ARN en la fisiopatología de los tumores hipofisarios: caracterización de nuevos biomarcadores y estrategias terapéuticas. Institución Financiadora: Proyecto Senior de la Fundación de la Sociedad Española de Endocrinología y Nutrición (FSEEN) Periodo, desde: 2022 a: 2024 Cantidad: 25.000 € IP: Raúl Miguel Luque Huertas
6. Título: Identificación de nuevos biomarcadores y estrategias terapéuticas en craneofaringiomas basadas en las maquinarias moleculares de control del metabolismo del ARN. Institución Financiadora Proyecto Senior de la Fundación de la Sociedad Española de Endocrinología y Nutrición (FSEEN) Periodo, desde: 2023 a: 2024 Cantidad: 10.000 € IP: Raúl Miguel Luque Huertas
7. Título: Estudio de la maquinaria celular del Inflamasoma en tumores hipofisarios: Aproximación clínica, molecular y funcional (SAEDYN03) Institución Financiadora: Sociedad Andaluza de Endocrinología, Diabetes y Nutrición (SAEDYN) Periodo, desde: 2023 a: 2024 Cantidad: 6.000 € IP: Raúl Miguel Luque Huertas
8. Título: Interacciones celulares y sistémicas entre el cáncer y la señalización metabólica (RED2022-134387-T). Institución Financiadora: Red de Investigación del Ministerio de Ciencia e Innovación Periodo, desde: 2023 a: 2025 Cantidad: 19.100 € IP y Coordinador: Raúl Miguel Luque Huertas
9. Título: Molecular and functional characterization of prostate and bladder cancer: search of novel therapies. Institución Financiadora (contrato con empresa): Eli Lilly & Company Periodo, desde: 2021 a: 2024 Cantidad: 74.800 € IP: Raúl Miguel Luque Huertas.
1. Fuentes-Fayos AC, G-García ME, Pérez-Gómez JM, Montero-Hidalgo AJ, Martín- Colom J, Doval-Rosa C, Blanco-Acevedo C, Torres E, Toledano-Delgado Á, Sánchez- Sánchez R, Peralbo-Santaella E, Ortega-Salas RM, Jiménez-Vacas JM, Tena- Sempere M, López M, Castaño JP, Gahete MD, Solivera J, Luque RM. 2023. Metformin and simvastatin exert additive antitumour effects in glioblastoma via senescence-state: clinical and translational evidence. EBioMedicine 90:104484. doi: 10.1016/j.ebiom.2023.104484. Factor de impacto: 11.1 (D1).
2. Fuentes-Fayos AC, Pérez-Gómez JM, G-García ME, Jiménez-Vacas JM, Blanco- Acevedo C, Sánchez-Sánchez R, Solivera J, Breunig JJ, Gahete MD, Castaño JP, Luque RM. 2022. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances. J Exp Clin Cancer Res 41(1):39. doi: 10.1186/s13046-022-02241-4. Factor de impacto: 11.3 (D1).
3. Fuentes-Fayos AC, Vázquez-Borrego MC, Jiménez-Vacas JM, Bejarano L, Pedraza- Arévalo S, L-López F, Blanco-Acevedo C, Sánchez-Sánchez R, Reyes O, Ventura S, Solivera J, Breunig JJ, Blasco MA, Gahete MD, Castaño JP, Luque RM. 2020. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3. Brain 143(11):3273-3293. doi: 10.1093/brain/awaa273. Factor de impacto: 14.5 (D1).
4. Vázquez-Borrego MC, Gupta V, Ibáñez-Costa A, Gahete MD, Venegas-Moreno E, Toledano-Delgado Á, Cano DA, Blanco-Acevedo C, Ortega-Salas R, Japón MA, Barrera-Martín A, Vasiljevic A, Hill J, Zhang S, Halem H, Solivera J, Raverot G, Gálvez MA, Soto-Moreno A, Paez-Pereda M, Culler MD, Castaño JP, Luque RM. 2020. A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors. Clin Cancer Res 26(4):957- 969. doi: 10.1158/1078-0432.CCR-19-2154. Factor de impacto: 11.5 (D1).
5. Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez- Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco- Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. 2017. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. Mol Cancer 16(1):146. doi: 10.1186/s12943-017-0713-9. Factor de impacto: 37.3 (D1).
Hormones and Cancer
Hormones and Cancer
- IP: Justo P. Castaño Fuentes
- Location:
- Edificio Severo Ochoa, 3ª planta. Campus de Rabanales. 14014. Córdoba.
- Edificio IMIBIC. Avda. Menéndez Pidal s/n. 14004 Córdoba.
- Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. - (+34) 957 21 37 43 - (+34) 659 38 67 98
- Web: enlace
- RRSS: @JustoCastano - @HYCLab
- IP:
JUSTO PASTOR CASTAÑO FUENTES
- INVESTIGADORES:
FRANCISCO GRACIA NAVARRO
ALEJANDRO IBAÑEZ COSTA
SERGIO PEDRAZA ARÉVALO
- PREDOCTORALES:
RICARDO BLAZQUEZ ENCINAS REY
M TRINIDAD MORENO MONTILLA
VICTOR GARCÍA VIOQUE
CLARA GONZÁLEZ PÉREZ
DANIEL RUIZ PALACIOS
The Hormones and Cancer research group investigates the cellular and molecular principles underlying the natural processes of neuroendocrine-metabolic regulation and their dysfunctions in tumors and cancer. The group pays special attention to the role played by certain neuropeptide/receptor systems and their regulation by distinct mechanisms, especially alternative splicing and its related RNA controlling processes and associated signalling pathways, at the onco-endocrine interface. The original focus of our group laid on the study of pituitary cell biology, particularly growth hormone (GH)-producing somatotropes and their regulatory signals (somatostatin, cortistatin, GHRH, ghrelin, Kisspeptins, etc.) and receptors (SST1-5, GHRHR, GHSR1, KISS1R), and signalling pathways. This line evolved to study pituitary adenomas and expanded definitely with the discovery of novel, abnormal splicing variants (SST5TMD4, In1-ghrelin) and the study of their pathophysiological role in somatotropinomas and other types of endocrine tumors and, broadly, in tumor development and metabolic dysfunction. Currently, our work is centred in the pathophysiology of neuroendocrine tumors (NETs) from pancreatic, gastrointestinal and lung origin, and of pancreatic ductal adenocarcinoma (PDAC), wherein we investigate the actions of diverse molecular regulatory systems (including somatostatin, ghrelin, etc.) and the specific role of alternative splicing and RNA biology. To achieve our goals, we use a wide range of techniques, including primary cultures of normal and tumor cells, cell lines, genetically modified animals, measurements of peptides, hormones, second messengers and gene expression of diverse molecular components, particularly of the spliceosome machinery, as well as dynamic imaging of molecular trafficking, confocal microscopy in living cells, etc. We are developing and applying biocomputational approaches to explore the spliceosomic landscape in different experimental and clinical settings with the aim of further understanding the contribution of splicing and RNA metabolism to cancer and other diseases.
1. RNA splicing as a key regulatory player with translational potential in neuroendocrine neoplasms (RNALYSEN). MICINN. PID2022-136227OB-I00. 287.500 € IP: JP Castaño. 2024-2026.
2. Splicing-derived neoantigens as targets for immunotherapy in pancreatic cancer (SplicInmuno). Pancreatic Cancer Association (ACANPAN), Spanish Association of Pancreatology (AESPANC), 7th Grant Carmen Delgado/Miguel Pérez-Mateo. (40.000,0€) PI: JP Castaño & A Ibáñez-Costa. 2022-2024.
3. Contribution of spliceosomic dysregulation to pancreatic cancer: underlying mechanisms and diagnostic and therapeutic potential. Universidad de Córdoba, FEDER. UCO- 202099901918904. (24.376,43 €). IP: JP Castaño, Co-IP A Ibáñez-Costa. 2022-2023.
4. Análisis molecular de la resistencia a análogos de somatostatina en feocromocitomas y paragangliomas. Grupo Español de Tumores Neuroendocrinos Y Endocrinos (GETNE; GETNE-JR- 2022-01) (20.000,0€) PI: A Ibáñez-Costa. 2023-2024.
5. Deciphering neuroendocrine tumour heterogeneity through a spliceosomic and RNA-biology approach: potential diagnostic and therapeutic value (SPLIRNANETS). MICINN. PID2019- 105201RB-I00. 215.622€ IP: JP Castaño. 2020-2022.
6. Spliceosomic strategy to improve the diagnostic, classification and treatment of pancreatic neuroendocrine tumours. Spanish Group for the Study of Endocrine and Neuroendocrine Tumours GETNE2019 Research Grant G1909. 60.000€ IP: JP Castaño. 2020-2022.
7.- Reconciling lung carcinoids histopathological and molecular classifications. NTRF-2022 Neuroendocrine Tumor Research Foundation PI: Matthieu Foll, IARC-Lyon. Role: JP Castaño, WP Receptor identification. ($270,000.00) (2023-2024).
8. Accelerating precision medicine in pancreatic cancer through definition of novel classifications and molecular targets. G 2021 ID 26343. Fondazione AIRC per la ricerca sul cancro. PI: Aldo Scarpa. University of Verona, ARC-NET. Role: JP Castaño. WP on Splicing. (1,147,000.00 €) (2022-2026)
- Ho KKY, Kaiser UB, Chanson P, Gadelha M, Wass J, Nieman L, Little A, Aghi MK, Raetzman L, Post K, Raverot G, Borowsky AD, Erickson D, Castaño JP, Laws ER, Zatelli MC, Sisco J, Esserman L, Yuen KCJ, Reincke M, Melmed S 2023 Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification. Nat Rev Endocrinol. 2023 Aug 17. doi: 10.1038/s41574-023-00883-8
- Pedraza-Arevalo S, Alors-Pérez E, Blázquez-Encinas R, Herrera-Martínez AD, Jiménez-Vacas JM, Fuentes-Fayos AC, Reyes Ó, Ventura S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, GálvezMoreno MA, Gahete MD, Ibáñez-Costa A, Luque RM, Castaño JP. 2022 Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors. Transl Res. Jul 23:S1931-5244(22)00170-0. doi: 10.1016/j.trsl.2022.07.005.
- Blázquez-Encinas R, Moreno-Montilla MT, García-Vioque V, Gracia-Navarro F, Alors-Pérez E, PedrazaArevalo S, Ibáñez-Costa A, Castaño JP. 2022 The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities. Rev Endocr Metab Disord. 24:1-16. doi: 10.1007/s11154-022-09771-4
- Alors-Perez E, Blázquez-Encinas R, Alcalá S, Viyuela-García C, Pedraza-Arevalo S, Herrero- Aguayo V, Jiménez-Vacas V, Mafficini A, Sánchez-Frías ME, Cano MT, Abollo-Jiménez F, Marín- SanzJA, CabezasSainz P, Lawlor RT, Luchini C, Sánchez L, Sánchez-Hidalgo JM, Ventura S, Martin-Hijano L, Gahete MD, Scarpa A, Arjona-Sanchez A, Ibáñez-Costa A, Sainz, Jr, B, Luque RM, Castaño JP. 2021 Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. J Exp Clin Cancer Res 40:382. doi.org/10.1186/s13046021-02153-9
- Pedraza-Arevalo S, Ibáñez-Costa A, Blázquez-Encinas R, Branco MR, Vázquez-Borrego MC, HerreraMartínez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-Sánchez Á, Gálvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Castaño JP. 2022 Epigenetic and posttranscriptional regulation of somatostatin receptor subtype 5 (SST5) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol. 16:764-779. doi: 10.1002/1878- 0261.13107
Adipobiology
Adipobiology. Metabolism and adipocyte differentiation. Metabolic syndrome.GC11
- IP: María del Mar Malagón Poyato
- Location:
- Edificio Severo Ochoa, 3ª planta. Campus de Rabanales. 14014. Córdoba.
- Edificio IMIBIC. Avda. Menéndez Pidal s/n. 14004 Córdoba.
- Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. - (+34) 957 21 37 77
- Web: enlace
- RRSS: @mardelmala - @anagordonbc - @ROCIOGRGC11
- IP:
María del Mar Malagón Poyato
- INVESTIGADORES:
Ana Gordon Bermúdez-Coronel
Rocio Guzmán Ruiz
María del Carmen Soler Vázquez
- PREDOCTORALES:
Jaime David López Alcalá
Elena Garrido Rascón
Olga García Ruiz
Samuel Lorenzo Pino
María González Ruiz
- PERSONAL TÉCNICO-ADMINISTRATIVO:
Elena Salido Martínez
The Adipobiology research team is a consolidated research group working on the identification and characterization of novel markers of adipose tissue dysfunction in obesity. Our research is aimed at elucidating the cellular and molecular mechanisms underlying the development of obesity-related comorbidities, including insulin resistance and type 2 diabetes. This research has a two-pronged approach: (a) targeted analyses of the regulation of insulin signaling and lipid storage and mobilization in adipocytes at the cellular and molecular levels, using a wide variety of cellular and molecular methodologies in adipocyte cell lines and human primary adipocytes, and (b) untargeted omics studies.
Our current research projects are aimed at characterizing the impact of extracellular matrix composition and remodeling on obesity-associated adipocyte dysfunction and the changes in macrophage phenotype that occur in response to obesogenic insults, in order to identify novel molecular mechanisms that could be useful for the diagnosis and/or treatment of obesity and metabolic diseases. In this context, we use 2D and 3D culture systems as platforms for testing drugs, biological fluids or nanotechnological products with the aim of translating research results to clinical applications. We employ in vitro models of insulin resistance to mimic different features of obesity and metabolic disease, as well as different approaches for the identification of protein networks relevant to adipose tissue function. We also explore the impact of the loss of function of intracellular compartments and their interactions network in adipocytes under obese conditions.
Fibrosis del Tejido Adiposo: regulación e impacto en la disfunción tisular y comunicación interórganos en obesidad y resistencia a insulina. PID2022-141964OB-I00. Convocatoria 2022 de proyectos de I+D+i, RETOS DE LA SOCIEDAD, MICINN (IMIBIC/Universidad de Córdoba). 2023-2025. IP: Maria del Mar Malagón.
Caracterización del matrisoma del tejido adiposo y papel de la remodelación de la matriz extracelular en la resistencia a insulina asociada a obesidad. PID2019-108403R. Convocatoria 2019 de proyectos de I+D+i, RETOS DE LA SOCIEDAD, MICINN (IMIBIC/Universidad de Córdoba). 2020-2024. IP: Maria del Mar Malagón.
Exploring the impact of obesity on intercellular and inter-tissue communication of adipose tissue to find novel therapeutic strategies. Acciones Individuales MSCA-Sello de Excelencia ISCIII-HEALTH (ISCIII). IHMC22/00002 (IMIBIC/Universidad de Córdoba). 2023-2025. IP: Ana Gordon.
- López-Alcalá J, Gordon A, Trávez A, Tercero-Alcázar C, Correa-Sáez A, González-Rellán MJ, Rangel-Zúñiga OA, Rodríguez A, Membrives A, Frühbeck G, Nogueiras R, Calzado MA, Guzmán- Ruiz R, Malagón MM. Localization, traffic and function of Rab34 in adipocyte lipid and endocrine functions. J Biomed Sci. 2024 Jan 5;31(1):2. doi: 10.1186/s12929-023-00990-8. PMID: 38183057
- Navarro-Ruiz MC, Lopez-Alcala J, Diaz-Ruiz A, Del Moral SD, Tercero-Alcazar C, Nieto-Calonge A, Lopez-Miranda J, Tinahones FJ, Malagon MM, Guzman-Ruiz R. Translational Research. 2022. DOI: 10.1016/j.trsl.2022.02.008
- Sanchez-Ceinos J, Guzman-Ruiz R, Rangel-Zuniga OA, Lopez-Alcala J, Moreno-Cano E, Del Rio- Moreno M, Romero-Cabrera JL, Perez-Martinez P, Maymo-Masip E, Vendrell J, Fernandez- Veledo S, Fernandez-Real JM, Laurencikiene J, Ryden M, Membrives A, Luque RM, Lopez- Miranda J, Malagon MM. Impaired mRNA splicing and proteostasis in preadipocytes in obesity- related metabolic disease. eLife. 2021. 10: e65996. DOI: 10.7554/eLife.65996.
- Sanchez-Ceinos J, Rangel-Zuniga OA, Clemente-Postigo M, Podadera-Herreros A, Camargo A, Alcala-Diaz JF, Guzman-Ruiz R, Lopez-Miranda J, Malagon MM. miR-223-3p as a potential biomarker and player for adipose tissue dysfunction preceding type 2 diabetes onset. Molecular Therapy-Nucleic Acids. 2021. 23:1035-1052. DOI: 10.1016/j.omtn.2021.01.014.
- Guzman-Ruiz R, Tercero-Alcazar C, Rabanal-Ruiz Y, Diaz-Ruiz A, El Bekay R, Rangel-Zuniga OA, Navarro-Ruiz MC, Molero L, Membrives A, Ruiz-Rabelo JF, Pandit A, Lopez-Miranda J, Tinahones FJ, Malagon MM. Adipose tissue depot-specific intracellular and extracellular cues contributing to insulin resistance in obese individuals. Faseb Journal. 2020. 34 (6):7520-7539 DOI: 10.1096/fj.201902703R
Molecular Hepatology
Molecular Hepatology
- IP: Manuel D. Gahete (Profesor Titular UCO)
- Location:
- Edificio Severo Ochoa, 3ª planta. Campus de Rabanales. 14014. Córdoba.
- Edificio IMIBIC. Avda. Menéndez Pidal s/n. 14004 Córdoba.
- Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. / This email address is being protected from spambots. You need JavaScript enabled to view it.
- Web: enlace
- RRSS: @MolHepatolGC30 - @ManuelDGahete
- IP:
Manuel D. Gahete (Profesor Titular UCO)
- INVESTIGADORES:
Dr. Juan L. López Cánovas
- PREDOCTORALES:
Natalia Hermán Sánchez
Betsaida Ojeda Pérez
Antonio García Estrada
Mª Isabel Pozo Relaño
- PERSONAL TÉCNICO-ADMINISTRATIVO:
Víctor Fernández Ramírez
The Molecular Hepatology Group investigates the cellular and molecular causes underlying the development of different liver pathologies. Indeed, the research of the Molecular Hepatology Group focuses on the study of the deregulation of gene expression control mechanisms, RNA biogenesis, mRNA metabolism (splicing, NMD, RNA-exosome, etc.) and protein synthesis and maturation in the development and progression of different liver pathologies such as fatty liver disease, cirrhosis or liver cancer. We also study the involvement of metabolic dysregulation (obesity, diabetes, metabolic syndrome) and, therefore, the associated cellular, molecular and endocrine systems (somatostatin, ghrelin, adipokines, hepatokines, etc.) in these liver pathologies. To this end, we use different genetic and cellular and molecular biology approaches, as well as cell culture techniques, preclinical animal models and clinical samples obtained through collaboration with different groups at IMIBIC and other centres. The ultimate goal of this research is to identify new molecular targets that can be used to improve the diagnosis of patients with liver diseases, to estimate their prognosis more accurately or to help develop new therapeutic approaches for their treatment. To this end, we have received continuous public and private funding over the last few years, which has resulted in the publication of several research articles and the establishment of patents that protect the possible clinical application of this research.
1. Título: Altered splicing process in chronic liver disease progression and hepatocarcinogenesis: novel source for diagnostic, prognostic and therapeutic targets (PI20/01301) Institución Financiadora: Instituto de Salud Carlos III (FIS – Proyectos en Salud) Periodo, desde: 2021 a: 2023 Cantidad: 183.920€ PI: Manuel D. Gahete
2. Título: Papel de los sistemas de regulación endocrina somatostatina y ghrelina en el desarrollo y progresión de la enfermedad de hígado graso asociada al metabolismo Institución Financiadora: Fundación de la Sociedad Española de Endocrinología y Nutrición (FSEEN) - Beca de ayuda a trabajos de investigación traslacional en endocrinología general y metabolismo Periodo, desde: 2022 a: 2022 Cantidad: 10.000€ PI: Manuel D. Gahete
3. Título: Aproximación multi-ómica para la identificación de nuevos y personalizados biomarcadores diagnósticos, pronósticos y terapéuticos en la interacción patológica entre obesidad y carcinoma hepatocelular (PEMP-0036- 2020) Institución Financiadora: Consejería de Salud y Familias de la Junta de Andalucía (Proyectos Fondos FEDER) Periodo, desde: 2022 a: 2023 Cantidad: 121.712€ PI: Manuel D. Gahete
4. Título: Impacto de la obesidad en la progresión de cirrosis a carcinoma hepatocelular (CHC): Identificación de los mecanismos moleculares y dianas terapéuticas (OBN22PI03/2022) Institución Financiadora: CIBEROBN-CIBEREHD (Proyectos Colaborativos) Periodo, desde: 2022 a: 2023 Cantidad: 49.900€ PI: Manuel D. Gahete
5. Título: Desarrollo de una herramienta para el diagnóstico y pronóstico en cánceres hormono-dependientes basada en el análisis de péptidos solubles derivados del receptor de somatostatina SST5TMD4 (DTS22/00057) Institución Financiadora: ISCIII – Proyecto DTS (Desarrollo Tecnológico en Salud) Periodo, desde: 2023 a: 2024 Cantidad: 84.700€ PI: Manuel D. Gahete
6. Título: Altered tRNA biogenesis process in chronic liver disease progression and hepatocarcinogenesis: novel source for diagnostic, prognostic and therapeutic targets (Liver-T) (PI23/00652) Institución Financiadora: Instituto de Salud Carlos III (FIS – Proyectos en Salud) Periodo, desde: 2024 a: 2026 Cantidad: 305.00€ PI: Manuel D. Gahete
1. López-Cánovas JL, Hermán-Sánchez N, Del Rio-Moreno M, Fuentes-Fayos AC, Lara- López A, Sánchez-Frias ME, Amado V, Ciria R, Briceño J, de la Mata M, Castaño JP, Rodriguez-Perálvarez M, Luque RM, Gahete MD*. PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing. Exp Mol Med. 2023; 55(1):132-142. doi: 10.1038/s12276- 022-00917-7. IF: 12,172. Ranking: 21 of 297 in Biochemistry and Molecular Biology (Q1/D1). *Autor de correspondencia.
2. López-Cánovas JL, Hermán-Sánchez N, Moreno-Montilla MT, Del Rio-Moreno M, Alors-Perez E, Sánchez-Frias ME, Amado V, Ciria R, Briceño J, de la Mata M, Castaño JP, Rodriguez-Perálvarez M, Luque RM, Gahete MD*. Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing. Clin Transl Med. 2022; 12(11):e1102. doi: 10.1002/ctm2.1102. IF: 8,554. Ranking: 41 of 245 in Oncology (Q1). *Autor de correspondencia.
3. López-Cánovas JL, Del Rio-Moreno M, García-Fernandez H, Jiménez-Vacas JM, Moreno-Montilla MT, Sánchez-Frias ME, Amado V, L-López F, Fondevila MF, Ciria R, Gómez-Luque I, Briceño J, Nogueiras R, de la Mata M, Castaño JP, Rodriguez- Perálvarez M, Luque RM, Gahete MD*. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. Cancer Lett. 2021; 496:72-83, doi: 10.1016/j.canlet.2020.10.010. IF: 9.756. Journal Ranking: 35 of 245 in Oncology (Q1). *Autor de correspondencia.
4. Del Río-Moreno M, Alors-Pérez E, González-Rubio S, Ferrín G, Reyes O, Rodríguez- Perálvarez M, Sánchez-Frías ME, Sánchez-Sánchez R, Ventura S, López-Miranda J, Kineman RD, de la Mata M, Castaño JP, Gahete MD*, Luque RM*. Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab 104(8): 3389-3402, 2019. doi: 10.1210/jc.2019-00021. PMID: 30901032. FI: 4.381. Journal Ranking: 21 of 143 in Endocrinology and Metabolism (Q1). *Autor de correspondencia.
5. Del Rio-Moreno M, Alors-Perez E, Borges de Souza P, Prados-Gonzalez ME, Castaño JP, Luque RM, Gahete MD*. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. Transl Res 211: 147-160, 2019. doi: 10.1016/j.trsl.2019.02.013. PMID: 30904441. FI: 5.411. Journal Ranking: 2 of 29 in Medical Laboratory Technology (Q1/D1). *Autor de correspondencia.